

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/19, 31/35, 31/13	A1	(11) International Publication Number: WO 94/03166 (43) International Publication Date: 17 February 1994 (17.02.94)
(21) International Application Number: PCT/US93/06726 (22) International Filing Date: 20 July 1993 (20.07.93) (30) Priority data: 921,882 29 July 1992 (29.07.92) US (60) Parent Application or Grant (63) Related by Continuation US 921,882 (CON) Filed on 29 July 1992 (29.07.92) (71) Applicants (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). MCNEIL-PPC, INC. [US/US]; Van Liew Avenue, Milltown, NJ 08850 (US).		(72) Inventors; and (75) Inventors/Applicants (for US only) : SIMS, Robert, T. [US/US]; 5080 Anderson Road, Holicong, PA 18928 (US). GATES, Thomas, N. [US/US]; 132 Sandywood Drive, Doylestown, PA 18901 (US). SLIVKA, William [US/US]; 9425 Meadowbrook Lane, Philadelphia, PA 19118 (US). (74) Agent: WINOKUR, Melvin; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: IBUPROFEN-MUSCLE RELAXANT COMBINATIONS (57) Abstract This invention relates to pharmaceutical compositions for use in the treatment of pain and inflammation and the treatment of muscle spasms and associated pain, soreness and tightness of muscles in mammalian organism, said composition comprising: (i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen; and (ii) an amount effective in the treatment of muscle spasms of at least one of the muscle relaxants, or a therapeutically active stereoisomer thereof, substantially free of its other stereoisomers.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic			SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	UA	Ukraine
DE	Germany	MG	Madagascar	US	United States of America
DK	Denmark	ML	Mali	UZ	Uzbekistan
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

5

- 1 -

10

TITLE OF THE INVENTION

IBUPROFEN-MUSCLE RELAXANT COMBINATIONS

BACKGROUND OF THE INVENTION

15

The non-steroidal anti-inflammatory drugs (NSAID) have been utilized in the treatment of pain/inflammation and have been disclosed as useful in the treatment, management and mitigation of cold symptoms and the pain associated therewith.

20

Ibuprofen (2-(4-isobutylphenyl)propionic acid) is a well known and commonly employed NSAID. Recently, it has been found that a faster onset of pain relief and an enhanced analgesic response can be obtained by the utilization of the single enantiomer (S)-ibuprofen in comparison to racemic ibuprofen, (see for example U.S. Patent 4,877,620).

25

30

- 2 -

Muscle relaxants are useful for the treatment of muscle spasms, and associated muscle pain, soreness and tightness, due to muscle strains, overexertion, and minor injuries of the back and neck. Both ibuprofen and muscle relaxants are also
5 useful in relieving the symptoms associated with menstrual associated disorders, such as cramping.

Combinations of ibuprofen with muscle relaxants have been disclosed; however, despite the fact that the muscle spasm sufferer is in need of
10 quick and enhanced relief there has been no consideration given to the employment of (S)-ibuprofen or a salt thereof, and more particularly a lysine or arginine salt thereof, in
15 combination with a muscle relaxant for the treatment of pain and the relief of muscle spasm symptoms.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to pharmaceutical compositions for use in the treatment of pain and inflammation and the treatment of muscle spasms and
20 associated muscle pain, soreness and tightness in a mammalian organism, said composition comprising:

(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof,
25 substantially free of (R)-ibuprofen; and

(ii) an amount effective in the treatment of muscle spasms of at least one of the muscle relaxants, or a therapeutically active stereoisomer thereof, substantially free of its other
30 stereoisomers.

- 3 -

This invention is also directed to a method of treating pain and inflammation and treating muscle spasm and associated symptoms in a mammalian organism in need of such treatment, comprising administering to such organism:

5

(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen; and

10

(ii) an amount effective in the treatment of muscle spasms of at least one of the muscle relaxants, or a therapeutically active stereoisomer thereof, substantially free of its other stereoisomers.

15

This invention is also directed to a method of eliciting an onset hastened and enhanced response for the treatment of pain and inflammation and the treatment of muscle spasm and associated symptoms in a mammalian organism in need of such treatment, comprising administering to such organism:

20

(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen; and

25

(ii) an amount effective in the treatment of muscle spasms of at least one of the muscle relaxants, or a therapeutically active stereoisomer thereof, substantially free of its other stereoisomers.

30

Substantially free of (R)-ibuprofen should be taken to mean that the ratio of (S)-ibuprofen to (R)-ibuprofen is at least 90:10. Substantially free with respect to a muscle relaxant stereoisomer should be taken to mean that the ratio of that stereoisomer

- 4 -

to all other stereoisomers of the muscle relaxant is at least 90:10.

Salts of (S)-ibuprofen include pharmaceutically acceptable salts which include salts with alkali metals, such as sodium or potassium, salts with alkaline earth metals, such as calcium, or salts with other metals such as magnesium, aluminum, iron, zinc, copper, nickel or cobalt.

Pharmaceutically acceptable salts of (S)-ibuprofen further include the amino acid salts, particularly the basic amino acids such as lysine or arginine. Specifically included within the above composition is (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine.

The term mammal or mammalian organism includes but is not limited to man, dog, cat, horse and cow.

The term treatment encompasses the complete range of therapeutically positive effects associated with pharmaceutical medication including reduction of, alleviation of and relief from the symptoms or illness which affect the organism.

(S)-Ibuprofen may be prepared following the procedures disclosed in U.S. Patent 4,877,620. Metal salts of ibuprofen may be obtained by contacting a hydroxide, or carbonate with ibuprofen. Amino acid salts of ibuprofen may be obtained by contacting an amino acid in solution with ibuprofen.

The pharmaceutical compositions of the present invention are useful in the treatment of pain and inflammation and the symptoms such as pain, soreness, tightness of muscles and skeletal-muscle spasms.

- 5 -

The utilization of (S)-ibuprofen in an analgesic/muscle relaxant combination offers significant advantages over the combination of racemic ibuprofen with a muscle relaxant.

5 (S)-Ibuprofen provides a faster onset of pain/inflammatory relief and an enhanced degree of relief compared to racemic ibuprofen. These benefits are increased in an (S)-ibuprofen/muscle relaxant combination as the muscle relaxant potentiates the
10 action of (S)-ibuprofen.

Furthermore, the absence of (R)-ibuprofen provides significant benefits. The allergic contraindications sometimes associated with ibuprofen administration are absent or reduced in a composition
15 wherein the (R)-ibuprofen is absent. Furthermore, the subject using the (S)-ibuprofen/muscle relaxant combination will no longer need to divert metabolic energy to the inversion of the (R)-enantiomer. Furthermore, the absence of (R)-ibuprofen in an
20 (S)-ibuprofen/muscle relaxant combination is particularly advantageous as a lesser metabolic burden is placed on the urogenital system for the excretion of the (R)-enantiomer or its metabolites. The absence of inversion reduces or eliminates the
25 formation and incorporation into fatty tissue of hybrid-ibuprofen containing triglycerides. The renal burden and renal toxicities sometimes associated with ibuprofen therapy are reduced or absent in a substantially (R)-ibuprofen free composition.

30

- 6 -

Where only a single stereoisomer of the muscle relaxant is active (therapeutically active stereoisomer), the absence of the inactive substances in the present composition avoids undesirable toxic interactions and clearly avoids the metabolism
5 necessary to remove the nonactive entity.

The absence of inactive enantiomers, particularly (R)-ibuprofen provides for significant size and weight advantages in a combination dosage form, particularly a sustained release dosage form.
10 Where a sustained release dosage of ibuprofen may have required 800 to 1000 mg, the employment of (S)-ibuprofen reduces the weight to 400 to 500 mg, and provides for a more practical size tablet for an
15 ibuprofen/muscle relaxant combination.

An effective amount of (S)-ibuprofen, or a salt thereof, for use in an unit dose composition of this invention may range from 50 to 800 mg (S)-ibuprofen. The preferred amount of (S)-ibuprofen
20 is about 100 to 400 mg. The amount of a salt such as (S)-ibuprofen-(S)-lysine is determined based on the amount of (S)-ibuprofen contained therein.

The muscle relaxant employed herein may be selected from either of the polysynaptic depressant type or the non-polysynaptic depressant type. The
25 polysynaptic depressant type of muscle relaxant exerts a selective action on the polysynaptic neuronal systems that control muscle tone, probably blocking or retarding the transmission of nervous
30 impulses in internuncial pathways with the spinal cord and at higher levels. The polysynaptic

- 7 -

depressant type of muscle relaxant or compounds with muscle relaxant activity include but are not limited to: carisoprodol, chlorzoxazone, cyclobenzaprine, dantrolene, diazepam, metaxalone, baclofen, quinine, orphenadrine and methocarbamol.

The non-polysynaptic depressant type of muscle relaxant includes compounds that act as depressants of muscle-spindle activity and compounds that act on α -motoneurons.

The pharmaceutically acceptable salt of the muscle relaxant may be employed in the instant invention. Such pharmaceutically acceptable salts include citrate, hydrochloride, sodium, sulfate and the like.

The preferred muscle relaxant is cyclobenzaprine hydrochloride.

Included within this invention are any diastereomers and/or enantiomers of the muscle relaxant. Where a particular therapeutically active stereoisomer is not commercially available it may be prepared following standard resolution chemistry from the available racemic mixture.

The amount of the muscle relaxant useful in the practice of the present invention may vary from about 1 mg to 750 mg depending on the specific muscle relaxant. The preferred amount of muscle relaxant is selected from a range 1 to 25 mg per tablet.

The present compositions may be administered in the form of tablets, caplets, gelcaps, capsules, elixirs, syrups or a suspension. For oral administration the active components may be admixed with a pharmaceutically acceptable diluent such as

- 8 -

lactose, starch, sucrose, cellulose, magnesium
stearate, dicalcium phosphate, calcium sulfate,
mannitol and in a liquid composition,
ethyl alcohol. Acceptable binders such as PVP,
5 starch, gelatin, natural sugars, corn sweeteners,
natural and synthetic gums such as acacia, sodium
alginate, carboxymethylcellulose, polyethylene glycol
and waxes, may also be admixed with the active
components. Where necessary lubricants such as
10 magnesium stearic acid talc, boric acid, sodium
benzoate, sodium acetate and sodium chloride, and
disintegrators such as starch, methylcellulose, agar,
bentonite and guar gum and super disintegrators such
as docusate sodium, sodium starch glycollate or
15 cross-linked PVP may also be included.

The active components may also be formulated
in sustained release formulations. These
formulations may be employed in oral, dermal, rectal
or vaginal administrations. Such sustained release
20 forms also include layered formulations which provide
for distinct release ratio and thus may be more
beneficial in allowing for short and long term relief.

The following examples illustrate the
compositions of the present invention and as such are
25 not to be considered as limiting the invention set
forth in the claims appended hereto.

30

- 9 -

EXAMPLE 1(S)-ibuprofen. Muscle Relaxant Tablet

5	(S)-ibuprofen-(S)-lysine	342 mg
	Cyclobenzaprine hydrochloride	5 mg
	PVP	15 mg
	Avicel PH101	40 mg
	Magnesium Stearate	4 mg

10

EXAMPLE 2(S)-ibuprofen. Muscle Relaxant Tablet

15	(S)-ibuprofen-(S)-lysine	342 mg
	Cyclobenzaprine hydrochloride	2.5 mg
	PVP	15 mg
	Avicel PH101	40 mg
	Magnesium Stearate	4 mg

20

EXAMPLE 3(S)-ibuprofen. Muscle Relaxant Sustained Release

25	(S)-ibuprofen	400 mg
	Cyclobenzaprine hydrochloride	5 mg
	PVP	30 mg
	Avicel PH101	80 mg
	Magnesium Stearate	8 mg
30	Methocel E10MCR	66 mg
	Methocel K100MLV	200 mg

- 10 -

EXAMPLE 4(S)-ibuprofen-(S)-lysine/Muscle Relaxant Solution

5	(S)-ibuprofen-(S)-lysine	342 mg
	Cyclobenzaprine hydrochloride	5 mg
	q.s. syrup	5 ml

10

15

20

25

30

- 11 -

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for use in the treatment of pain and inflammation and the treatment of muscle spasms and associated pain, soreness and tightness of muscles in a mammalian organism and adapted for unit dosage oral administration, said composition comprising:
 - (i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen; and
 - (ii) an amount effective in the treatment of muscle spasms, and associated symptoms, of at least one muscle relaxant, or a therapeutically active stereoisomer thereof, substantially free of its other stereoisomers.
2. A composition of Claim 1 where the ibuprofen is present as the salt (S)-ibuprofen-(S)-lysine, or (S)-ibuprofen-(R)-lysine.
3. A composition of Claim 1 comprising at least 50 mg of (S)-ibuprofen.
4. A composition of Claim 1 wherein the muscle relaxant is selected from: baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, dantrolene, diazepam, methocarbamol, metaxalone, orphenadrine and quinine, or a pharmaceutically acceptable salt.
5. A composition of Claim 4 wherein the muscle relaxant is cyclobenzaprine hydrochloride.

- 12 -

6. A method of treating pain and inflammation and treating muscle spasms and associated pain, soreness and tightness of muscles in a mammalian organism in need of such treatment, comprising administering to such organism:

(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen;

(ii) an amount effective in the treatment of muscle spasms, and associated symptoms, of at least one muscle relaxant, or a therapeutically active stereoisomer thereof, substantially free of its other stereoisomers.

7. A method of eliciting an onset hastened and enhanced response for the treatment of pain and inflammation and the treatment of muscle spasms and associated pain, soreness and tightness of muscles in a mammalian organism in need of such treatment, comprising administering to such organism.

(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen; and

(ii) an amount effective in the treatment of muscle spasms, and associated symptoms, of at least one muscle relaxant, or a therapeutically active stereoisomer thereof, substantially free of its other stereoisomers.

8. A method of reducing the side effects associated with the administration of an ibuprofen/muscle relaxant combination which comprises

- 13 -

the administration of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen, and at least one muscle relaxant or a therapeutically active stereoisomer thereof substantially free of its other stereoisomers.

5

9. A method of reducing the size and weight of an ibuprofen/muscle relaxant combination dosage form which comprises combining (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen and at least one muscle relaxant or a therapeutically active stereoisomer thereof substantially free of its other stereoisomers.

10

15

20

25

30

INTERNATIONAL SEARCH REPORT

INTERNATIONAL APPLICATION NO.
PCT/US93/06726**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) :A61K 31/19, 31/35, 31/13

US CL :514/570, 656, 659, 649

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. :

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS - Ibuprofen and cyclobenzaprine

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,877,620 (Loew et al.) 31 October 1989, see entire document, especially column 1, line 13 to column 3, line 15.	1-9
Y	US, A, 4,780,463- (Sunshine et al.) 25 October 1988, see entire document, specially claim 12.	1-9
Y	US, A, 5,124,355 (Tully et al.) 23 June 1992, see entire document.	1, 12, 13, 18, 19
Y	US, A, 5,034,405 (Jakubowski) 23 July 1991, see entire document.	1, 6, 7, 12, 13, 18, 19

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A document defining the general state of the art which is not considered to be part of particular relevance	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E earlier document published on or after the international filing date	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* G	document member of the same patent family
* O document referring to an oral disclosure, use, exhibition or other means		
* P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

21 OCTOBER 1993

Date of mailing of the international search report

NOV 02 1993

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

T.J. CRIARES ACH

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-1235